Donepezil from Actavis first to eight EU markets as patents expire

Donepezil from Actavis first to eight EU markets as patents expire

Actavis today announced the launch of Donepezil in some of Europe's biggest markets, immediately after the patents expired. The conventional tablets were launched in Germany, France, Italy, Spain, the UK, Denmark, Sweden and Austria this week.

Donepezil tablets were developed by Actavis R&D and manufactured by Actavis in Malta.

Actavis is also bringing Donepezil oro-dispersible tablets to market following patent expiry in the UK and Sweden.

Actavis has already launched Donepezil in a number of patent-free markets.

Donepezil is indicated for the treatment of mild to moderately severe Alzheimer's disease. Donepezil Actavis is the generic equivalent of the brand product Aricept® from Pfizer.

The Brand product had sales in the EU of approximately EUR 475.6mln for the 12 months ending September 2011, according to IMS Health.


Actavis Group
Hjordis Arnadottir
Director - External Communications
Tel: +41 41 462 7300
E-mail: [email protected]


Suggested Articles

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.